Obolenskoye FP ZAO (Alium)

JSC Alium (formerly FP Obolenskoye), which is part of the group AFK Sistema the Russian pharmaceutical , is a company engaged in the development, production and promotion of drugs in accordance with GMP standards and. ISO

JSC Alium combines the assets of JSC FP Obolenskoye and JSC Binnopharm under the Alium brand.

As of September 2024, ALIUM specializes in the production of prescription and over-the-counter drugs of various therapeutic groups in the forms of tablets, capsules and sachets: pulmonology, neurology, cardiology, gastroenterology, infectious and colds, phlebology, urology, antibiotics and antiseptics, painkillers. ALIUM is an enterprise with a total area of ​ ​ 25,000 square meters. m, where more than 650 people work.

History

2024: Alium accounts for 50% of Binopharm Group's sales in money and 30% in packaging

ALIUME produces portfolio bestsellers - billionaire brands, as well as a wide list of popular drugs. According to Binnopharm Group, in the first half of 2024, the share of products produced at the ALIUM plant amounted to 50% of the company's sales in money and 30% in packaging.

Anatoly Yaglenko, Corporate Director for Production Activities of Binnopharm Group: "In the near future, we plan to implement a project at the plant to build a new granulation site with a capacity of 15-20 million packages per year. This will allow the site to reach a new level in the production of granular preparations. "

2023

Install additional production lines to increase output by 32%

In 2023, Binnopharm Group increased its production capacity for the production of capsules at the ALIUM plant, installing additional lines, which made it possible to increase the production of capsule products by 54%, and in general, products by 32%. In addition, in 2023, the site carried out a transfer of 21 products.

Northern State Medical University Student Internship

Students Northern State Medical University undergo internships at the situated near Moscow pharmaceutical factories "Alium" (Obolensk) and "" Binnopharm(), Zelenograd which are part of "." Binnopharm Group They study the technology of production and quality management of medicines, which will provide an opportunity to get closer acquainted pharmaceutical industry with and gain skills in working on specialized equipment. Binnopharm Group announced this on February 16, 2023. More. here

2022

Increase in the production of medicinal products to 64.5 million packages

In 2022, the Alium production site (part of Binnopharm Group) increased the production of medicines to 64.5 million packages, or 25% compared to the results of 2021. The company expands the product line in more convenient packages and dosages. Since November 2022, the production of painkillers and antipyretics has been increasing. Binnopharm Group announced this on February 9, 2023.

In 2022, the Alium plant launched 13 drugs, including vital and important drugs, as well as drugs designed to treat hypertension in adults, anthelmintic and antiprotozoans, diuretics, antipyretics, anti-inflammatory and painkillers. The total sales of drugs in 2022 amounted to about 1.5 billion rubles.

In July 2022, Alium began releasing Alfaxime, a Russian generic rifaximin, an antibiotic designed to treat bowel disease. Gastroenterology is one of the key activities of the enterprise, which produces more than 20 prescription and over-the-counter drugs of this direction. The first export product produced at Alium was the Neobutin antispasmodic (trimebutin), which was launched on the Azerbaijani market in 2023.

In 2023, the Alium production site will continue to expand - increasing volumes and expanding product lines. Among other things, the production of drugs for export will increase - in 2023 more than 70 new positions will be introduced. Exports will be carried out to the EAEU countries, as well as to the Republic of Uzbekistan and Moldova, said Rustem Muratov, CEO of Binnopharm Group.

In February 2023, the company will complete the modernization of the site for the production of drugs in capsules. In 2022, Omeprazole became the leader among them, the volume of drug production increased by 50% - to 10.5 million packages.

Release of 3 billion tablets and capsules

The Alium plant near Moscow on March 16, 2022 announced that since 2019 it has produced more than 3 billion tablets and capsules, which is equivalent to 150 million packages or 1200 tons of medicines, and was one of the first in Russia to launch a QR-code drug labeling system. The total volume of production at the enterprise since the beginning of 2019 has grown by almost a third.

The launch of the production site of the Alium plant took place in February 2019. The total volume investments in the implementation of the project at that time amounted to 3 billion rubles. The project was supported - Government of the Moscow Region the investor was provided with a subsidy to compensate for the costs of creating engineering infrastructure. Also, a grace period to taxes for profit and property was provided for the enterprise. As of March 2022, we have a large modern pharmaceutical production in the region, where more than 500 employees are employed, - said Deputy Prime Minister - Minister of Investment, Industry and Science of the Moscow Region Ekaterina Zinovieva.

As of March 2022, the Alium plant produces more than 200 names of high-quality generic drugs of various therapeutic groups. Binnopharm Group constantly invests in the development of its production sites, expanding their technological capabilities and increasing production capacities. So, in 2021, the company installed a line for the production of sachets, where anti-stool, non-steroidal anti-inflammatory and other drugs will be made. Investments in the project amounted to 100 million rubles.

In 2022, the company plans to launch the production of a number of drugs, including vital ones. The new drugs will complement the Binnopharm Group portfolio and expand the existing line of medicines for the treatment of arterial hypertension, bronchial asthma and allergic rhinitis, and other diseases.

2021

Modernization of the production of drugs in the form of sachets for 100 million rubles

The pharmaceutical company Binnopharm Group (part of the AFK Sistema Group) on December 14, 2021 announced that it had modernized the site for the production of sachets at the Alium plant in the village of Obolensk, Moscow Region, increasing its capacity to 50 million sachets per year. The company plans to gradually transfer the production of all its sachets to the Alium plant. Investments in the project amounted to 100 million rubles.

"One of our strategic objectives is to find possible synergies between production sites to optimize processes and improve operational efficiency. Step-by-step consolidation of the production of drugs in sachets at the Alium plant in the Moscow region, where we have completely reorganized the site for the production of this form, is one example of such synergy, "said Rustem Muratov, General Director of Binnopharm Group. - First, it is planned to produce the anti-vessel drug Flukomp at the modernized site, later the production of the drug Colds will be transferred to the Moscow region. "

According to Rustem Muratov, the form of sachet in the segment of symptomatic drugs for ARVI is the most popular among the end consumer: about 70% of demand is for sachet and only 30% for tablets.

By the end of 2022, Binnopharm Group will begin producing three more sachet drugs at Alium, including the nonsteroidal anti-inflammatory drug Naisulid.

Triple the production capacity of capsules

On February 4, 2021, the Binnopharm Group pharmaceutical holding announced on February 4, 2021 that it was tripling its production capacity for the production of capsules at the Alium plant in the village of Obolensk, Moscow Region, to 15 million packages per year.

This will significantly increase the production of drugs for the prevention, treatment, as well as recovery of the body after COVID-19, as well as increase the production of drugs of various therapeutic directions - diuretic drugs, antidiarrheal and antiulcer drugs, agents for the treatment of obesity, hepatoprotectors, antifungal and other drugs.

It was possible to increase production capacity thanks to the reorganization and redevelopment of the capsule operating area, where an additional encapsulation machine is installed. In 2020, the line worked at the limit of production capacity, including because it makes the antibiotic "Azithromycin," recommended in the protocols for the treatment of COVID-19. At the same time, we feel the need to increase the production of drugs of other pharmacological groups, - says Rustem Muratov, General Director of Binnopharm Group..

According to the results of 2020, at the site in the village of Obolensk, the production of the antibiotic "Azithromycin" has been increased by more than 5 times. The medicinal product is produced, among other things, in the form of capsules.

2020

Start-up of small-scale production area

The Binnopharm Group pharmaceutical holding, which unites the portfolio companies AFK Sistema - JSC Alium (includes JSC Binnopharm) and OJSC Sintez (includes CJSC Biocom), has launched a small-scale production site at the Alium plant in Obolensk, Moscow Region. This was announced on November 11, 2020 by Sintez OJSC. The site is designed to create small batches of medicines, which will unload the main production and increase the economic efficiency of the enterprise.

The production of more than 25 types of drugs has been postponed to this site (4 are included in VED), which are used to treat not the most common, but socially significant diseases. For example, "Mipexol" is used in Parkinson's disease, "Azurix" is a generic German drug for the treatment of gout, "Relef" is prescribed to patients with rheumatoid and psoriatic arthritis.

{{quote 'There are a number of drugs in the Alium portfolio that are in demand, but in relatively small volumes. It is economically feasible for us to produce them at a small-scale production site, the capacity of which is 50-100 kg of tablets per day, freeing up the capacity of production lines for larger products. This is the only way to achieve operational efficiency, which is the main goal for the management of companies, - commented Rustem Muratov, General Director of Binnopharm Group. }}

Inclusion of JSC Alium in Binopharm Group Holding

On October 30, 2020, Sintez informed Zdrav.Expert that the pharmaceutical holding, which unites the portfolio companies of AFK Sistema - Alium JSC (includes Binnopharm JSC) and Sintez OJSC (includes Biocom CJSC), announced strategic directions of development. The holding will operate under the Binnopharm Group brand. Read more here.

Transfer of asset management to Alium Group

On July 20, 2020, PJSC AFK Sistema announced the creation of the company Alium groups"," which transferred stakes in the Corporation pharmaceutical in the companies OJSC "" Synthesis(owns CJSC "") and Biolump JSC "Alium" (combines the assets of JSC FP "Obolenskoye" and JSC "" under the Alium brand Binnopharm). More. here

2019

Synthesis and Biocom will merge with FP Obolenskoye and Binnopharm

Marathon Group and AFK Sistema closed the acquisition of pharmaceutical companies Sintez and Biocom. This was announced on August 8, 2019 by the Marathon Group. OJSC Sintez and CJSC Biocom together with Alium - a combined pharmaceutical company created by AFK Sistema on the basis of JSC FP Obolenskoye and JSC Binnopharm - can form a major player with the potential to enter the top 3 Russian pharmaceutical companies in the commercial segment. The joint product portfolio of OJSC Sintez, CJSC Biocom and Alium will include more than 500 items, and production facilities are represented by six pharmaceutical production complexes in Moscow and the Moscow region, Kurgan and Stavropol. Read more here

Creation of the joint pharmaceutical company Alium

According to information as of June 14, 2019, a joint pharmaceutical company Alium is being created on the basis of the pharmaceutical enterprise Obolenskoye and Binnopharma.

2018: AFK Sistema bought a stake in FP Obolenskoye

On December 28, 2018, AFK Sistema, a public Russian diversified holding company, acquired a stake in Pharmaceutical Enterprise Obolenskoye JSC. The stake was acquired jointly with VTB Bank and OBL Pharm management from Alvansa Ltd, whose main shareholders are Gazprombank and UFG Private Equity.

2015

Start of the investment program for the modernization of the production complex

In 2015, an investment program began to modernize and expand the production complex of the enterprise in order to increase the production of already produced drugs and new pharmaceutical products. Development of some sites of partner companies for the production of drugs of JSC FP Obolenskoye.

Purchase of Urdox and Novobismol brands

In 2015, the company purchased the Urdox and Novobismol brands from the pharmaceutical company Pharmproekt JSC (St. Petersburg).

2014: OOO "Segment Pharm" joined the FP "Obolenskoye"

In April 2014, the Holding Company included LLC Segment Farm. Thus, FP "Obolenskoye" expands its assortment due to drugs that are not limited by the volume of its own production.

Segment is Pharmaceutics a promising company with an interesting portfolio of innovative drugs (Maxilak®, Adecta®, Evakyu®, Thrombovazim®), many of which have no analogues on the Russian market.

The product portfolio of the combined company includes more than 100 names of drugs that meet all modern standards of quality, effectiveness and safety: drugs for the treatment of cardiovascular diseases, diseases of the gastrointestinal tract, antiallergic, antiviral drugs, as well as drugs of other clinical areas. Following consumer demand trends, the range of drugs is constantly expanding.

JSC FP Obolenskoye also produces a wide range of socially significant drugs. The budget department of the enterprise supplies to all regions of the Russian Federation under Regional and Federal programs of compulsory drug provision (ONLS), as well as centralized hospital procurement.

2013

At the end of 2013, the Alvansa pharmaceutical holding was established on the basis of the Obolenskoye production enterprise, the main shareholders of which are currently Gazprombank and the UFG Private Equity investment fund.

In 2013, FP Obolenskoye underwent two external audits confirming the compliance of the quality of products and the quality management system (QMS) with the requirements of international standards GMPEU and ISO. The construction of an integrated quality management system in accordance with GMP requirements and conditions and ISO standards is explained by the active development of the company to increase the production of medicines.

1994: Establishment of an enterprise

JSC Pharmaceutical Enterprise Obolenskoye (FP Obolenskoye) was founded in September 1994 on the basis of the State Scientific Center for Applied Microbiology, located in the village of Obolensk, Serpukhov District, Moscow Region.